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Abstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without 
incontinence, generally accompanied by an increase in urinary frequency and nocturia, after 
any local disease or metabolic disorder that would explain these symptoms have been ruled 
out, is a highly prevalent condition that affects millions of men and women worldwide. Not 
only can the symptoms of OAB be very bothersome, but OAB can have significant detri-
mental effects on many aspects of individuals’ lives, representing a particularly impactful 
health burden to quality of life and productivity. Besides a wide range of conservative 
treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the 
mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects 
like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are 
common reasons of abandonment of treatment. An alternative to oral administration treat-
ment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might 
be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin 
directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass 
hepatic metabolism that occurs with orally administered oxybutynin and prevents the 
appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral 
treatment improves adherence, persistence, and patient satisfaction. The aim of this review is 
to focus on evidence available of the use of OXY-TDS in the management of patients with 
OAB, and to help clinicians in the challenges involved in the treatment options for patients 
with this condition. 
Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal 
oxybutynin
Background
Overactive bladder (OAB) defined by urinary urgency with or without urge incon-
tinence, often accompanied by frequency and nocturia1 is a prevalent condition both 
in men and women. In the EPIC study, the largest population-based survey in five 
countries (Canada, Sweden, Germany, Italy, and the UK), the overall prevalence of 
OAB was 11.8%, with similar rates in men and women, and increasing with age.2 
In the 2013, data from 31,763,561 beneficiaries in the Medicare fee-for-service 
population in the United States, the prevalence of OAB was 7.2%, but projected to 
increase by 48.8% from 2013 to 2027.3 Other population-based studies have shown 
prevalences of OAB around 16%.4,5 In the EpiLUTS study conducted in the US, 
UK, and Sweden, the overall prevalence of lower urinary tract symptoms (LUTS) 
was 24.7% when symptoms were defined as “often” and 35.6% when defined as 
sometimes.6,7 OAB with combined urge incontinence and/or LUTS have 
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a substantial multidimensional impact on patients (quality 
of life, work productivity, sexuality, physical and emo-
tional well-being) and economic burden on health-care 
systems, with important public health and clinical manage-
ment implications to maximize treatment options and opti-
mize patient outcomes.8
The use of anticholinergics has been the mainstay of 
managing OAB for years. Anticholinergic agents block 
postganglionic muscarinic receptors with variable selectiv-
ity for different receptor subtypes, decreasing bladder con-
tractility, reducing intravesical pressure, and raising the 
volume threshold for micturition.9 However, because 
anticholinergic receptors are found throughout the body, 
the side effects of these drugs are common and wide-
spread. Side effects, including dry mouth, blurry vision, 
dry eye or constipation associated with oral formulations 
have been shown to be a primary reason for discontinuing 
OAB medications.10 In clinical practice, only a minority of 
patients persist with anticholinergic medication beyond 
6 months. Persistence or compliance with pharmacother-
apy remains a significant barrier to effectively managing 
OAB.11 These difficulties have led to the development of 
alternative formulations. Transdermal oxybutynin (OXY- 
TDS) bypasses the first-pass metabolism and reduces the 
formation of N-desethyloxybutynin (N-DEO), a compound 
believed to be associated with anticholinergic side 
effects.12 OXY-TDS is a valuable option instead of oral 
anticholinergics for patients who are at risk or who have 
experienced dry mouth with oral agents.13,14
In this review, we aimed to present the current evi-
dence of OXY-TDS in the management of OAB available 
in the literature to date, with a focus on relevant data 
regarding efficacy, safety, adherence, persistence, and 
patient satisfaction. We also aimed to provide an overview 
on how OXY-TDS can be integrated into clinical practice 
to help clinicians towards problems and challenges related 
to management of patients with OAB in real-world clinical 
settings.
OXY-TDS Mechanism of Action and 
Pharmacokinetics
Oxybutynin (OXY) is tertiary amine with a twofold 
mechanism of action: antimuscarinic properties, with selec-
tivity for M1 and M3 receptors, and spasmolytic action on 
detrusor smooth muscle cells.15–17 The salivary glands, in 
particular, have M3 receptors which account for the high 
rate of dry mouth experienced by patients treated with oral 
OXY. Although OXY has been consistently shown to be 
superior to placebo in randomized double-blind clinical 
trials,18,19 dry mouth is especially an important side effect 
limiting its use in clinical practice. OXY-TDS is a matrix- 
type patch composed of a backing film, an adhesive/drug 
layer, and release liner (dosage 39 cm2 patch delivering an 
average dose of 3.9 mg per 24 h). Administration of OXY- 
TDS, twice a week, has been licensed for use by the US 
FDA in 2003, and authorized on June 15, 2004 by the 
European Medicines Agency. In the EU, OXY-TDS is 
approved for symptomatic treatment of urge incontinence 
and/or increased urinary frequency and urgency in patients 
with OAB.
The OXY is absorbed by the capillary microcirculation 
of the skin dermis and delivered into the systemic circula-
tion bypassing first-pass metabolism in the liver. 
Therefore, the conversion of OXY to its main metabolite 
N-DEO is reduced. By contrast, following oral adminis-
tration, OXY undergoes extensive first-pass metabolism in 
the liver and an additional portion is metabolized within 
the lumen of the gastrointestinal tract. Hepatic CYP3A4 
cytochrome converts OXY to N-DEO, with N-DEO reach-
ing plasma concentrations 4 to 10 times higher than those 
of native OXY.20 Side effects of OXY, in particular dry 
mouth, are related to the high affinity of N-DEO to bind 
muscarinic receptors in the parotid gland.21
The OXY-TDS system provides continuous delivery of 
OXY over 96 hours, and the drug is detectable in plasma 
after 2 hours following patch application. Steady-state is 
achieved during the second patch application period. In 
a study of the pharmacokinetics of OXY-TDS and an 
extended-release oral OXY, mean plasma concentrations 
were less variable during OXY-TDS and the ratio of area 
under the curve was significantly lower as compared with 
extended-release oral administration.22 Mean saliva output 
was greater during transdermal use compared with 
extended-release oral OXY, and significantly lower 
N-DEO concentration during OXY-TDS application was 
also associated with greater saliva output.22 Saliva output 
is a valid surrogate marker of dry mouth.23 In vitro skin 
flux studies showed that both enantiomers of OXY are 
absorbed equally across human epidermis.24 Also, bioe-
quivalence has been demonstrated for the absorption of 
OXY with the patch application to the buttock or the 
abdomen.25 In an excellent review of Baldwin and 
Keating,26 extensive data of the pharmacokinetic and phar-
macodynamic profile of OXY-TDS has been reported.
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Therapeutic Efficacy
Clinical Trials
In 2001, Davila et al27 reported the results of a Phase II, 
6-week multicenter randomized double-blind dose titration 
study, in which the efficacy and safety of OXY-TDS 
(1.3 mg/day) was compared with oral immediate release 
OXY (2.5 mg) in 74 adult volunteers with urge urinary 
incontinence. The efficacy of both treatment arms was 
similar (decrease of daily incontinence episodes, visual 
analog scale [VAS] assessment for reduction of urinary 
leakage), but dry mouth occurred in 38% of patients in the 
OXY-TDS arm and in 94% in the OXY group (P < 0.001). 
Of the patients in the OXY-TDS group, a reduction in dry 
mouth severity compared with previous oral treatment was 
reported by 67% of patients and 90% had no or mild skin 
erythema.
The therapeutic efficacy of OXY-TDS has been eval-
uated in two Phase III randomized double-blind trials of 
the Transdermal Oxybutynin Study Group.28,29 In 2002, 
Dmochowski et al28 published the results of a comparison 
of OXY-TDS and placebo over 12 weeks followed by an 
open label extension of 12 weeks in 520 patients with 
OAB and urge or mixed urinary incontinence. 
Statistically significant differences were found in all effi-
cacy variables (number of incontinence episodes per week, 
average daily urinary frequency, average urinary volume 
per void), as well as in improvements in the quality of life 
(Incontinence Impact Questionnaire [IIQ] and Urogenital 
Distress Inventory [UDI]).28 The occurrence of dry mouth 
was similar in both groups and pruritus in the application 
site was the most common side effect in the OXY-TDS 
group. In 2003, Dmochowski et al29 conducted another 
randomized double-blind, double-dummy clinical trial, in 
which OXY-TDS and long-acting oral tolterodine (TOL- 
LA) and placebo were compared in 361 patients with OAB 
and urge and mixed urinary incontinence. OXY-TDS and 
TOL-LA were effective and comparable treatments, with 
statistically significant differences in all efficacy variables 
versus placebo.29 The duration of the study was 12 weeks 
and the efficacy endpoints were the same than in the 
previous randomized trial.28 OXY-TDS improved systemic 
safety with regard to anticholinergic side effects.
In a combined analysis of the results of these two 
randomized trials, 241 patients received OXY-TDS 
(3.9 mg/day) and 244 placebo,30 daily urinary inconti-
nence episodes and daily urinary frequency showed 
a 75% and 18% reduction in the OXY-TDS group and 
a 50% and 8.7% reduction in the placebo group, respec-
tively (P = 0.0004 and P = 0.0023). Decreases in incon-
tinence episodes were already observed within the first 2–3 
weeks of treatment (at the first evaluation) and were sus-
tained throughout the study. Increases in urinary void 
volume were 15% and 3.6%, respectively (P < 0.0001). 
Improvements in health-related quality of life (HRQoL) 
showed significant differences in the IIQ total score in 
favor of OXY-TDS, whereas improvements in the UDI 
questionnaire were similar. Integrated safety outcomes 
confirmed data of the individual trials.
In a 4-week randomized double-blind study of 96 
women with ≥3 month history of OAB treated with OXY- 
TDS (3.9 mg/day) or placebo, five patient-selected goals 
were established as the primary outcome measure.31 There 
were no significant difference in the mean goal achieve-
ment between OXY-TDS and placebo (41.9% vs 32.2%), 
probably attributed to the small sample size. However, 
decreases in daily urgency episodes and urge incontinence 
were significantly greater for women assigned to OXY- 
TDS. Improvements in HRQoL (King’s Health 
Questionnaire) were similar. In a further 12-week rando-
mized double-blind clinical trial with 1530 patients with 
OAB syndrome, in which OXY-TDS, oral propiverine 
(20 mg) and placebo were compared, OXY-TDS was non- 
inferior to propiverine and statistically significantly better 
than placebo in all outcome measures.32 The incidence of 
dry mouth and constipation was higher with propiverine 
than with the oxybutynin patch or placebo, although site 
dermatitis was more frequent with the oxybutynin patch. 
Details of all these trials are shown in Table 1.
Effectiveness of OXY-TDS in Clinical 
Practice
The transdermal (TDS) Oxybutynin (Oxytrol(r)) in 
Overactive Bladder (MATRIX) study33 was an open-label, 
prospective, randomized, community-based multicenter 
cohort study of 2878 adults with OAB enrolled at 327 
centers throughout the USA. The duration of the study 
was 6 months. Study sites were randomized 1:1 within the 
investigators’ medical specialty to provide standard instruc-
tions or educational intervention (a packet of educational 
materials with each month’s supply of OXY-TDS). Specific 
main outcomes included the impact of OXY-TDS on 
HRQoL, work productivity, and sexual function, but parti-
cipant-reported perceptions of bladder condition were also 
evaluated. Using the Patient Perception Bladder Condition 
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(PPBC), 22.7% of patients scored less severe OAB symp-
toms (PPBC score 1, 2 or 3) at baseline increasing to 57.5% 
at 6 months.33 The percentage of patients with more severe 
OAB symptoms (PPBC score 4, 5 or 6) decreased from 
77.3% to 42.5%. Moreover, at baseline 16.5% of partici-
pants felt that they “always” had enough time to get to the 
bathroom during the past month, a percentage that almost 
doubled after 1 month of treatment (33.9%) and increased to 
44.1% at 6 months.33
In 2018, Vozmediano-Chicharro et al34 reported the find-
ings of The Oxybutynin-transdermal in Standard ClinicAl 
pRactice study (OSCAR study), which was a retrospective 




Design Population Treatment and 
Duration
Outcome Measures Results




74 volunteers with 
detrusor instability






episodes, visual analog scale 
(VAS) for efficacy, dry 
mouth symptoms, 
multichannel cystometry
Decrease of incontinence episodes 
66% OXY-TDS vs 72% OXY 
(P=0.39), VAS reduction urinary leak 
similar in both groups, dry mouth 
occurred in 38% OXY-TDS vs 95% 
OXY (P<0.001), similar 






520 patients with 










week, average daily urinary 
frequency, average urinary 
volume/void, quality of life
Median change of incontinence 
episodes/week from −19.0 to −14.5 
(P=0.01), mean decrease daily 
urinary frequency −2.3±2.5 vs −1.7 
±3.0 with placebo (P=0.04), median 
increase urinary volume/void 
+24 mL vs +6 mL (P=0.006), 
substantial improvement in quality of 







361 patients with 






(TOL-LA) (4 mg/ 
day) vs placebo 
12 weeks
Incontinence episodes/ 
week, average daily urinary 
frequency, average urinary 
volume/void, quality of life
Reductions of incontinence episodes 
in OXY-TDS (−3) and TOL-LA (−3) 
vs placebo (−2) (P<0.05); average 
void volume increase (24 and 29 mL 






96 women with ≥ 3 








Five patient-selected goals: 
range of OAB symptoms 
and quality of life 
impairment
Improvement in urgency episodes/ 
day (−1.23 vs −0.21, P=0.01) and 
urge incontinence episodes/day 
(−0.47 vs −0.23, P=0.04). No 
differences in nocturia. Similar 








1530 patients with 
OAB symptoms ≥ 












OXY-TDS vs placebo: micturitions/ 
day −1.89 and −1.44 (P=0.001); 
urgency episodes −1.92 and −1.51 
(P=0.006); urge incontinence −1.06 
and −0.88 (P=0.01); voided volume 
23.25 and 11.84 mL (P<0.001); 
greater improvement in KHQ. OXY- 
TDS non-inferior to propiverine
Abbreviations: KHQ, King’s Health Questionnaire; OAB, overactive bladder; OXY, oxybutynin; OXY-TDS, transdermal oxybutynin; TOL-LA, long-acting oral tolterodine; 
VAS, visual analog scale.
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cohort study conducted in daily practice in three Spanish 
centers from the same health-care regions in Spain. Data of 
105 patients diagnosed with OAB were reviewed and 
changes in symptoms of OAB after 12 months of treatment 
as compared with baseline were evaluated, primarily with 
a 3-day voiding diary. Significant improvements were 
observed in urinary frequency (−2.6 voids/day, 95% CI 
−3.5 to −1.8, P < 0.001), number of urgent episodes/day 
(−4.7, 95% CI −6.1 to −3.6, P < 0.001), and urge incon-
tinence (−1.9 episodes/day, 95% CI −2.9 to −1.3, P < 0.001). 
Improvements in the International Consultation on 
Incontinence Questionnaire-Short Form (ICIQ-SF) were sig-
nificant as compared with baseline. In the subanalysis of 
naïve versus non-naïve patients and patients <65 years and 
≥65 years, statistically significant differences were not 
observed. Only 5.7% of patients reported dry mouth and 
pruritus and/or erythema at the application site was recorded 
in 27.6% of patients.
In relation to HRQoL, which has been consistently 
included as secondary endpoint in the randomized clinical 
trials,27–32 change in HRQoL using the KHQ instrument 
from baseline to the end of the study was a primary end-
point of the MATRIX study.35 In 2592 evaluable patients, 
Incontinence Impact, Symptom Severity, and Sleep/Energy 
were the most impaired domains at baseline. At 6 months, 
clinically meaningful and statistically significant improve-
ments in 9 of the 10 domains were recorded, with greatest 
improvements in Incontinence Impact (−13.5), Symptom 
Severity (−12.4), and Role Limitations (−13.3). These 
improvements were observed regardless of baseline char-
acteristics, such as men with and without pre-existing 
prostate problems (benign prostatic hyperplasia), patients 
who received enhanced education materials, patients aged 
<75 years and those ≥75 years, as well as in a subset of 
participants aged 85 years or older.33–36
The impact of OXY-TDS on work productivity among 
1112 working adults (mean age 52.4 years) enrolled in the 
MATRIX study has been evaluated using the Work 
Productivity Questionnaire (WPQ).37 The WPQ captures 
four physical or emotional barriers in the past 2 weeks 
associated with physical tasks, time management (routine 
and working without breaks), mental (focusing on work 
without wandering thoughts), and output demands (accom-
plishment of assigned tasks and/or performing to one’s 
potential). An overall WPQ Index Score is calculated to 
estimate the overall productivity loss. After treatment with 
OXY-TDS, significant improvements in all mean scores for 
all WPQ scales from baseline to the end of the study were 
found (P ≤ 0.0002). The mean overall WPQ Index Score 
decreased from 8.2 to 5.5 (P < 0.0001), and mean productiv-
ity loss scores decreased from 7.7% to 5.2% (P < 0.0001). It 
was estimated that for a full-time employee working 40 
hours/week, a reduction in productivity loss of 2.5% is 
equivalent to a gain of approximately 52 hours/year.
The effect of OXY-TDS on sexual function was also 
evaluated in the population of the MATRIX study using the 
KHQ instrument and the Beck Depression Inventory II.38 
The percentage of subjects who said that they leak during 
intercourse decreased from 22.8% to 19.3%. Regarding the 
effects of OAB on other domains, such as loss of interest in 
sex, effect of relationship with partner, effect on sex life, 
and embarrassment, paired analysis of the percent of sub-
jects with improvement versus those who stayed the same 
or worsened from baseline to end of study showed signifi-
cant differences in all domains (P < 0.001). The comparison 
of reductions of recurrent urinary tract infection and bladder 
pain was also significant (P < 0.001). The MATRIX study 
also demonstrated that complete loss of interest in sex was 
associated with older age, prolonged OAB symptoms, his-
tory of prior OAB therapy, and menopausal status in the 
women, and with age and duration of OAB symptoms 
in men.
Safety and Tolerability
Relevant safety outcomes reported in the randomized dou-
ble-blind clinical trials and in the OSCAR and MATRIX 
studies are detailed in Table 2. Findings from safety ana-
lyses of patients included in the randomized double-blind 
trials indicate that OXY-TDS is safe and well tolerated. 
The most common adverse event was application site 
reactions (erythema or pruritus) in the OXY-TDS arm as 
compared with placebo or TOL-LA, although the rate of 
anticholinergic adverse events experienced with OXY- 
TDS (eg, dry mouth, constipation) was low and not sig-
nificantly different from placebo. Most cases of local skin 
reaction were of mild to moderate intensity and resolved 
with topical corticosteroids or antihistamines. The rate of 
discontinuation due to erythema was 3.7% and due to 
pruritus 3.3%.30 Of note, that none of the patients with-
drew from the trials because of dry mouth, a common 
reason for discontinuation from oral anticholinergic 
therapy.
In studies carried out in clinical practice conditions 
(Table 2), OXY-TDS was also well tolerated and safe. In 
the MATRIX study,33 safety analysis was performed in the 
total population of 2878 patients with OAB who received 
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Design Population Treatment and 
Duration




Randomized double-blind 520 patients with 








OXY-TDS vs placebo 
Application site reactions:
● Erythema 5.6% vs 2.3%
● Pruritus 16.8% vs 6.1%  
Discontinuation 10.2% dur-
ing the double-blind period 
and 7.3% during the open 
label phase
OXY-TDS vs placebo
● Dry mouth 9.6% vs 8.3%
● Dizziness 4.0% vs 3.8%
● Somnolence 1.6% vs 0.8%
● Nausea 1.6% vs 5.3%
● Constipation 0.8% vs 
3.0%
● Palpitations 0.8% vs 0%






361 patients with 
OAB and urge or 
mixed urinary 
incontinence
OXY-TDS and long- 
acting oral 
tolterodine (TOL- 
LA) (4 mg/day) vs 
placebo 
12 weeks
OXY-TDS vs placebo 
Application site reactions:
● Erythema 8.3% vs 1.7%
● Pruritus 14.0% vs 4.3%  
Discontinuation 10.7%
OXY-TDS vs placebo
● Dry mouth 4.1% vs 1.7%
● Constipation 3.3% vs 0% 
TOL-LA vs placebo:
● Dry mouth 7.3% vs 1.7%
● Constipation 5.7% vs 0%
Sand, 200735 Open-label, prospective, 
randomized, community- 
based multicenter cohort 
study (MATRIX study)




● Symptomatic adverse 
events 30% (mild 14.7%, 
moderate 11.3%, severe 
4.0%)











● Blurred vision 0.6%






Randomized double-blind 96 women with ≥ 





At least one adverse event 




● Placebo 27.1%  
Discontinuation 7.3%
Systemic adverse events (at 
least 1):
● OXY-TDS 7 (14.9%) 
patients (dry mouth the 
most common)





1530 patients with 
OAB symptoms ≥ 
24 weeks, ≥ 8 
micturitions daily
OXY-TDS and oral 
propiverine (20 mg/ 
day) vs placebo 
12 weeks
● Symptomatic adverse 
events (non-application 
site) 32.2% OXY-TDS, 
41.0% propiverine, 32.0% 
placebo
● Symptomatic application 
site events 40.2% OXY- 
TDS, 10.2% propiverine, 
8.9% placebo
● Application site dermatitis 
31.8% OXY-TDS, 5.9% 
propiverine, 5.2% placebo
● Dry mouth 6.5% OXY- 
TDS, 13.2% propiverine, 
1.8% placebo
● Constipation 0.7% OXY- 
TDS, 5.0% propiverine, 
1.0% placebo
(Continued)
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at least one dose of OXY-TDS.35 Adverse events during 
the 6-month study period occurred in 30% of the partici-
pants but most events were mild or moderate. Application 
site reactions were experienced by 14% of patients, with 
around 4.5% rates of pruritus, erythema, and dermatitis. 
Dry mouth occurred in only 2.6% of cases. The incidence 
and distribution of adverse events were similar in specific 
populations of the MATRIX study, such as male patients 
with prostate conditions33 and older adults.36 Interestingly, 
the authors thought that explicit instructions given to sub-
jects to rotate application site each time a patch is applied 
was the reason for the low incidence of skin reactions 
observed in older adults, including the subsets of patients 
aged ≥75 and ≥85 years of age.36 In the OSCAR study, 
local site reactions were the most common (27.6%), parti-
cularly pruritus and irritated skin, in contrast to anticholi-
nergic adverse events which were uncommon (dry mouth 
5.7%).39 Most adverse events were mild or moderate, and 
only two cases of irritated skin were considered clinically 
relevant.
A recent network meta-analysis of randomized controlled 
trials of anticholinergic drug treatment for people with OAB 
included 128 studies evaluating several anticholinergic drugs 
(tolterodine, oxybutynin, trospium, propiverine, solifenacin, 
darifenacin, imidafenacin and fesoterodine).40 Although the 
effects of anticholinergics for the treatment of OAB on 
incontinence episodes and voids per day were clinically 
similar, OXY-TDS caused less dry mouth than the other 
treatments, so may be worth considering as the first 
treatment.
Cognitive Impairment
Cognitive side effects, such as confusion, changes in 
memory, blurred vision, or somnolence are related to 
blockage of M1 anticholinergic receptors in the central 
nervous system (CNS). There is evidence that treatment 
with anticholinergic drugs increases the risk of develop-
ing cognitive impairment and incident dementia,41,42 
which is particularly a matter of concern in older patients 
due to a lower number of anticholinergic receptors in the 
CNS, increased permeability of blood-brain barrier, and 
modification in drug metabolism secondary to aging, 
together with the possibility of higher anticholinergic 
burden due to frequent concomitant medication in this 
population. OXY-TDS reduces the production of its main 
metabolite N-DEO, which may account for a significant 
reduction of anticholinergic adverse events. In an obser-
vational retrospective multicenter study, 70 patients with 
OAB aged 65–80 years (mean age 71.4 ± 4.5 years) 
treated with OXY-TDS underwent assessment of cogni-
tive function before and after 1 month of treatment.43 The 
Memory Alteration Test (M@T) and the Clock-Drawing 
Test (CDT) questionnaires were used to assess cognitive 
function. Differences in the percentages of patients who 
did not have cognitive impairment before and after start-
ing OXY-TDS treatment were not statistically significant 
(M@T-test 88.6% vs 91.4%, P = 0.727; CDT test 91.4% 
vs 88.6%, P = 0.687). No worsening was observed in the 
M@T or CDT scores. Despite the limitation of the small 
sample size and the retrospective design, this study shows 
that there is no risk of cognitive impairment in older 
patients treated with OXY-TDS in the short term. 
Moreover, there seems to be no risk of cognitive impair-
ment in the long term as shown by the absence of 
cognitive decline in 51.4% of patients from the OSCAR 
study39 who completed the Mini-Mental State 
Examination (MMSE30) at least after 1 year of treatment 
with OXY-TDS. However, in contrast to the previous 




Design Population Treatment and 
Duration





Retrospective cohort study 
(OSCAR study) in daily 
practice




● Symptomatic adverse 
events 38.1%
● Symptomatic application 
site events 27.6%: pruritus 
15.2%, erythema 3.8%, 
irritated skin 12.4%
● Discontinuation 44.7%





Abbreviations: OAB, overactive bladder; OXY-TDS, transdermal oxybutynin; TOL-LA, long-acting oral tolterodine.
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study of Müller-Arteaga et al,43 the population of the 
OSCAR study was not limited to patients older than 65 
years of age.39
Persistence, Adherence and Patient 
Satisfaction
Persistence of treatment with OXY-TDS assessed by the rate 
of discontinuation was 7.3% in the 4-week randomized study 
of Cartwright et al,31 10.7% in the 12-week randomized trial of 
Dmochowski et al,29 and 16.5% in the MATRIX study.35 The 
highest rate of discontinuation of 44.8% was reported in the 
12-month OSCAR study,39 in which reasons for withdrawal 
were adverse events (40.9%), lack of clinical response 
(38.7%), and non-compliance with treatment (9.1%). In this 
study, 29.5% of discontinuations occurred within the 6 months 
after starting OXY-TDS treatment.
Validated questionnaires to measure adherence to OXY- 
TDS have been used occasionally. The study of Müller- 
Arteaga et al43 aimed to assess short-term changes in 
cognitive function in 70 elderly patients with OAB treated 
with OXY-TDS, is the only study in which adherence was 
evaluated using the Morisky-Green test. This study shows 
that 87.1% of patients stated that they had not forgotten to 
apply the patch any day, 84.3% that they changed the patch 
on the right day, and 92.9% that they did not stop applying 
the patch regardless of their state of health. Therefore, there 
was a high adherence rate as shown by 84.3% of patients 
who stated to change the patch on the right day, considering 
the non-interventional nature of an observational study.43
Patient satisfaction with OXY-TDS treatment has been 
also very high. In the study of Staskin et al33 of 369 male 
patients of the MATRIX study with underlying prostate 
conditions, 61.6% and 71.3% were “very satisfied” or 
“satisfied” with treatment and only 8.6% were “dissatis-
fied”. Also, 60.6% said that the patch offered significant 
benefits over previous treatments. In the OSCAR study, 
satisfaction with treatment was assessed in 58 patients who 
completed at least 12 months of treatment,39 using 
a 5-item questionnaire specifically designed for the study 
and a 0–10 scale for comfortability (10 as the best possible 
comfort). A total of 92.3% of patients considered that they 
felt comfortable with the patch, 87.7% that OXY-TDS did 
not or rarely affect daily activities, and 66.7% that if they 
could choose between taking a pill and using the patch, 
they would choose the patch. The mean rate of comfort-
ability for the OXY-TDS patch was 8.7 ± 1.6, being 10 the 
best possible comfort.
Other Aspects
In spinal cord injury patients with neurogenic detrusor over-
activity, OXY-TDS has been shown to be efficacious. In 
24 patients included in a multicenter, open-label, dose- 
titration study, OXY-TDS was tolerated at up to 3 times the 
standard dose (11.7 mg/day) and was associated with 
a statistically significant increase of clean intermittent cathe-
terization (CIC), CIC volume, reflex volume, maximal cysto-
metric bladder capacity, and residual urine volume, whereas 
detrusor pressure at maximal bladder capacity decreased sig-
nificantly. The most common adverse events were application 
site reaction (12.5% of patients), dry mouth (8.3%), and 
abnormal vision (8.3%) but no patient discontinued treatment 
because of an adverse event.44 Another study driven by 
Cartwright et al45 using transdermal and oral oxybutynin in 
children with neurogenic detrusor overactivity showed that 
OXY-TDS was a well-tolerated and effective alternative to 
oral oxybutynin in treating NDO in children who previously 
tolerated oxybutynin. The study included 57 patients. OXY- 
TDS significantly increased the percentage of leakage-free 
catheterizations and urine volume and resulted in significant 
improvement in all measured urodynamic parameters.
Treatment of OAB with OXY-TDS has been evaluated 
under the economic perspective of the Spanish health care 
system (2017) using a Markov model for a 5-year time hor-
izon compared to fesoterodine, tolterodine, solifenacin, oxy-
butynin, trospium chloride, and mirabegron.46 After 1 year, 
OXY-TDS showed greater persistence because of its better 
risk/benefit balance compared to muscarinic antagonists and 
mirabegron, and at 5 years led to more QALYs gained and 
was a highly cost-effective treatment, with an incremental 
cost-effectiveness ratio well below the thresholds assumed in 
Spain.
Concluding Remarks
OAB is currently a highly prevalent medical condition, 
usually of chronic course, and expecting to increase given 
population aging and rising life expectancy. Not only can the 
symptoms of OAB be very bothersome, but OAB has sig-
nificant detrimental effects on many aspects of the patients, 
in particular health-related quality of life. Fear of embarrass-
ment leads to social isolation and adaptive behaviors such as 
avoiding travel or social activities. Oral oxybutynin has been 
widely used to treat OAB but untoward anticholinergic side 
effects provided an impetus for the development of OXY- 
TDS, which reduces side effects and has equal efficacy and 
tolerability. The 3.9 mg matrix transdermal system is applied 
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twice weekly and transports OXY directly into the systemic 
circulation. The efficacy and safety of OXY-TDS found in 
phase III clinical trials have been confirmed in cohorts of 
patients with OAB attended in daily practice. Besides sig-
nificant improvements in the constellation of OAB-related 
symptoms, OXY-TDS has been shown to significantly 
improve HRQoL, sexual function, marital relationships, as 
well as to enhance work productivity. The incidence of antic-
holinergic adverse events with OXY-TDS is similar to pla-
cebo, and most common adverse events are mild-to- 
moderate skin reactions at the application site, improving 
treatment adherence. Counseling on healthy skin care and 
appropriate product use can enhance patients’ knowledge 
about OXY-TDS for OAB treatment and reduce the risk of 
these skin adverse effects.
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